Results 141 to 150 of about 36,538 (247)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu   +4 more
wiley   +1 more source

Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin‐like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling

open access: yesJournal of Diabetes Investigation, EarlyView.
Molecular mechanism of synergistic antagonism of ANGPTL4 and VEGF by ginsenoside Rg3 combined with ranibizumab, regulating the NRP/RhoA pathway to inhibit macular edema. ABSTRACT Aims This study investigated the molecular mechanisms by which ginsenoside Rg3 combined with ranibizumab alleviates diabetic macular edema (DME), focusing on antagonizing ...
Jiexin Yu, Xingyu Li, Yanli Liu
wiley   +1 more source

Association between thyroid dysfunction and cognitive impairment in type 2 diabetes mellitus: A cross‐sectional study

open access: yesJournal of Diabetes Investigation, EarlyView.
Hypothyroidism is an independent risk factor for cognitive impairment in T2DM patients, with a progressive risk increase associated with higher TSH levels. These findings underscore the importance of integrating thyroid function evaluation into the cognitive assessment and management strategy for this patient population.
Mengmeng Zheng, Xing Zhong, Ping Zhang
wiley   +1 more source

Pregabalin efficacy in painful diabetic peripheral neuropathy: A focused analysis of optimal dosing and the relationship of baseline glycemic control

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Diabetic neuropathy, the most common long‐term complication of diabetes, frequently presents as painful diabetic peripheral neuropathy (pDPN), significantly impairing patients' quality of life. Pregabalin is an established treatment for pDPN, but optimal dosing and the influence of glycemic control on efficacy remain uncertain ...
Ashish Bajaj   +6 more
wiley   +1 more source

Role of the UHRF1–KLHL6–CORO2B axis in obesity‐related insulin resistance

open access: yesJournal of Diabetes Investigation, EarlyView.
In high‐fat diet (HFD)‐induced obese mice with insulin resistance, overexpression of UHRF1 may recruit DNMT1 to promote DNA methylation of KLHL6, leading to its downregulation. Subsequently, suppression of KLHL6 may decrease the ubiquitination of CORO2B, resulting in elevated CORO2B protein levels.
Xu Deng   +5 more
wiley   +1 more source

ChREBP drives β‐cell proliferation under metabolic stress but not in pregnancy‐induced β‐cell expansion

open access: yesJournal of Diabetes Investigation, EarlyView.
ChREBP is a context‐dependent regulator of adaptive β‐cell proliferation. It plays a pivotal role in driving β‐cell expansion under pathophysiological metabolic stress, such as insulin resistance and hyperglycemia, but has a limited role during physiological expansion in pregnancy.
Sodai Kubota   +20 more
wiley   +1 more source

Life‐threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry‐based cross‐sectional study

open access: yesJournal of Diabetes Investigation, EarlyView.
Despite insulin therapy, 18.8 and 7.8% of the patients experienced diabetic ketosis and diabetic ketoacidosis, respectively. Furthermore, 12.7 and 28.9% of the participants experienced severe hypoglycemia and hypoglycemic unawareness, respectively. Lower C‐peptide levels were associated with the incidence of these complications.
Daisuke Chujo   +7 more
wiley   +1 more source

Effects of imeglimin on experimental diabetic neuropathy in streptozotocin‐induced diabetic rats

open access: yesJournal of Diabetes Investigation, EarlyView.
Imeglimin exerted neuroprotective effects in a type 1 diabetic neuropathy model, improving sensory nerve conduction, sciatic nerve blood flow, and intraepidermal nerve fiber density. In vitro, imeglimin promoted neurite outgrowth in a DRG‐derived hybridoma cell line, supporting a direct neurotrophic action.
Wataru Nihei   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy